These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23229421)

  • 21. Exploring novel approaches to vaginal drug delivery.
    Gupta S; Gabrani R; Ali J; Dang S
    Recent Pat Drug Deliv Formul; 2011 May; 5(2):82-94. PubMed ID: 21413924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
    Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
    Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.
    Novara G; Galfano A; Secco S; D'Elia C; Cavalleri S; Ficarra V; Artibani W
    Eur Urol; 2008 Oct; 54(4):740-63. PubMed ID: 18632201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxybutynin: past, present, and future.
    Jirschele K; Sand PK
    Int Urogynecol J; 2013 Apr; 24(4):595-604. PubMed ID: 22976530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction.
    Choi JB; Jeon SH; Kwon EB; Bae WJ; Cho HJ; Ha US; Hong SH; Lee JY; Kim SW
    BMC Urol; 2020 Apr; 20(1):41. PubMed ID: 32303205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.
    Wang CC; Jiang YH; Kuo HC
    Low Urin Tract Symptoms; 2017 Jan; 9(1):27-32. PubMed ID: 28120445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic management of overactive bladder.
    Lam S; Hilas O
    Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C; Chapple C; Mueller ER; Robinson D; Rolland C; Staskin D; Stoelzel M; Maanen RV; Siddiqui E
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
    Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
    Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
    Ko Y; Malone DC; Armstrong EP
    Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health Related Quality of Life in Patients with Side-Effects after Antimuscarinic Treatment for Overactive Bladder.
    Kim A; Lee KS; Jung R; Na S; Kim JC; Kim HG; Choo MS
    Low Urin Tract Symptoms; 2017 Sep; 9(3):171-175. PubMed ID: 27291463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.
    Abrams P; Andersson KE; Buccafusco JJ; Chapple C; de Groat WC; Fryer AD; Kay G; Laties A; Nathanson NM; Pasricha PJ; Wein AJ
    Br J Pharmacol; 2006 Jul; 148(5):565-78. PubMed ID: 16751797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and future pharmacotherapy for treating overactive bladder.
    Thiagamoorthy G; Cardozo L; Robinson D
    Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.
    Villacampa F; Ruiz MA; Errando C; Arlandis S; Arumí D; Lizarraga I; Rejas J
    Int Urogynecol J; 2013 Apr; 24(4):573-81. PubMed ID: 23111865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment.
    Decalf VH; Huion AMJ; Benoit DF; Denys MA; Petrovic M; Everaert KCMM
    Drugs Aging; 2017 Aug; 34(8):615-623. PubMed ID: 28656509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
    McKeage K
    Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evolution of transdermal therapy for overactive bladder.
    Sand PK
    Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.
    Rovner ES; Wein AJ
    Eur Urol; 2002 Jan; 41(1):6-14. PubMed ID: 11999467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overactive bladder treatments in early phase clinical trials.
    Colli E; Digesu GA; Olivieri L
    Expert Opin Investig Drugs; 2007 Jul; 16(7):999-1007. PubMed ID: 17594185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.